* Fractional exhaled Nitric Oxide
For US Healthcare Professionals Only
For questions about coronavirus/COVID-19 and using NIOX VERO®, please visit the NIOX VERO Coronavirus/COVID-19 FAQ.
For over 20 years, NIOX® technology has aided healthcare professionals by accurately measuring airway inflammation in approximately 1 minute at the point of care.
Reassuring reproducibility enables an accurate result to be delivered in a single test.2 Inquire about NIOX VERO via our website to get in touch with our dedicated US sales team.
While airway inflammation is a major underlying characteristic of asthma, there are few methods which directly measure this. Evaluating airway inflammation using sputum eosinophils or airway biopsy can be expensive, invasive, time-consuming, and is often not readily available. FeNO testing provides a fast and accurate method to support diagnosis and management of asthma.
The majority of patients with asthma have Type 2/eosinophilic driven airway inflammation.4 The associated higher levels of nitric oxide (NO) in their exhaled breath can be simply measured to support optimal management of the condition.5
References: 1. Data on file. Circassia Ltd. October 2019 C-NIOX-0002. 2. Alving K et al. Validation of a New Portable Exhaled Nitric Oxide Analyzer, NIOX VERO®: Randomized Studies in Asthma. Pulm Ther. 2017 3(1):207-218. 3. Labeling Summary/Package Insert NIOX VERO® (EU). 000247-07, Nov 2017 4. Circassia White Paper. Summary of Evidence Supporting the Clinical Value of Monitoring Exhaled Nitric Oxide (FeNO) in the Management of Asthma. 2018 5. National Institute for Health and Clinical Excellence (NICE). Asthma: diagnosis, monitoring and chronic asthma management. NICE guideline [NG80]. 2017.